A 52-Week Study to Assess the Effects of MK0822 on Knee Osteoarthritis (MK-0822-011)

Merck Sharp & Dohme (MSD)

Status and phase

Terminated

Phase 2

Conditions

Osteoarthritis

Treatments

Drug: MK0822

Study type

Interventional

Funder types

Industry

Identifiers

NCT00397683

0822-011

2006_517

Details and patient eligibility

About

The purpose of this study is to test MK0822 on disease activity in patients with osteoarthritis in the knee. Disease modifying activity of MK0822 will be assessed by measurements of knee cartilage using Magnetic Resonance Imaging (MRI) of the knee.

This is an early phase trial and some specific protocol information is proprietary and not publicly available at this time. (Full information is available to trial participants).

Enrollment

2 patients

Sex

All

Ages

40+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with symptomatic knee osteoarthritis for at least 6 months based on clinical and radiographic criteria
Patients should be in general good health and must have a certain level of knee pain or be taking pain medicines on most days
Specific radiographic (X-ray) and MRI features must also be satisfied

Exclusion criteria

Non-osteoarthritic causes of knee pain
Ineligibility to undergo MRI of the knee due to patient tolerability or safety reasons
Previous septic arthritis, tibial osteotomy or knee replacement in both knees
Acute injury of knee ligaments or meniscus in past 2 years
Knee arthroscopy in past 12 months
Anticipated arthroscopy or surgery in next 18 months
Use of intra-articular injections of hyaluronan (e.g. Hyalgan (TM), Synvisc (TM), Orthovisc (TM)) in past 6 months, or injections of glucocorticoids (e.g. Kenalog (TM), Aristospan (TM), Depo-Medrol (TM)) in past 3 months or anticipated knee injections during the study
Glucosamine or chondroitin sulfate are allowable if they are at a stable dose for past 3 months and will continue at that dose during the study
Other exclusion criteria apply-Please ask the study doctor for details